Rapamycin is an effective inhibitor of human renal cancer metastasis.

Authors:
Fu L Luan
Fu L Luan
University of Michigan
Ann Arbor | United States
Ruchuang Ding
Ruchuang Ding
Weill Medical College of Cornell University
New York | United States
Vijay K Sharma
Vijay K Sharma
National University Health System
Singapore | Singapore
Milagros Lagman
Milagros Lagman
United States
Manikkam Suthanthiran
Manikkam Suthanthiran
Weill Cornell Medical College
New York | United States

Kidney Int 2003 Mar;63(3):917-26

Department of Medicine, Weill Medical College of Cornell University, New York-Presbyterian Hospital New York, New York, USA.

Unlabelled: Rapamycin is an effective inhibitor of human renal cancer metastasis.

Background: Human renal cell cancer (RCC) is common and is 10 to 100 times more frequent in patients with end-stage renal disease (ESRD) and candidates for renal transplantation. Treatment of metastatic RCC is largely ineffective and is further undermined by immunosuppressive therapy in transplant recipients. A treatment regimen that prevents transplant rejection while constraining RCC progression would be of high value.

Methods: We developed a human RCC pulmonary metastasis model using human RCC 786-O as the tumor challenge and the severe combined immunodeficient (SCID) beige mouse as the host. We explored the effect of rapamycin, cyclosporine, or rapamycin plus cyclosporine on the development of pulmonary metastases and survival. The effects of the drugs on tumor cell growth, apoptosis, and expression of vascular endothelial growth factor (VEGF-A) and transforming growth factor beta1 (TGF-beta1) were also investigated.

Results: Rapamycin reduced, whereas cyclosporine increased, the number of pulmonary metastases. Rapamycin was effective in cyclosporine-treated mice, and rapamycin or rapamycin plus cyclosporine prolonged survival. Rapamycin growth arrested RCC 786-O at the G1 phase and reduced VEGF-A expression. Immunostaining of lung tissues for von Willebrand factor was minimal and circulating levels of VEGF-A and TGF-beta1 were lower in the rapamycin-treated mice compared to untreated or cyclosporine-treated mice.

Conclusion: Our findings support the idea that rapamycin may be of value for patients with RCC and that its antitumor efficacy is realized by cell cycle arrest and targeted reduction of VEGF-A and TGF-beta1. A regimen of rapamycin and cyclosporine, demonstrated to be effective in reducing acute rejection of renal allografts, may prevent RCC progression as well, and has the potential to prevent mortality due to RCC in patients with ESRD who have received renal allografts.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1523-1755.2003.00805.xDOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
March 2003
35 Reads
43 Citations
8.563 Impact Factor

Publication Analysis

Top Keywords

rapamycin cyclosporine
16
human renal
12
rapamycin effective
12
rapamycin
11
rcc
9
pulmonary metastases
8
renal allografts
8
rcc progression
8
human rcc
8
vegf-a tgf-beta1
8
renal cancer
8
growth factor
8
effective inhibitor
8
rcc 786-o
8
inhibitor human
8
renal
7
human
5
cyclosporine
5
lower rapamycin-treated
4
cyclosporine rapamycin
4

Altmetric Statistics

Similar Publications